Short Leukocyte Telomere Length Predicts Albuminuria Progression in Individuals With Type 2 Diabetes

Resham Lal Gurung¹, Yiamunaa M¹, Sylvia Liu¹, Jian-Jun Liu¹ and Su Chi Lim¹,² for the SMART2D study

¹Clinical Research Unit, Khoo Teck Puat Hospital, Singapore; and ²Diabetes Centre, Khoo Teck Puat Hospital, Singapore

Introduction: Telomere length, a marker for biological aging, is implicated with diabetic kidney disease (DKD); however, the association between telomere length and albuminuria progression among Asian patients with type 2 diabetes (T2D) is not well understood. Here, we aim to study whether leukocyte telomere length (LTL) may independently predict albuminuria progression in patients with T2D with preserved renal filtration function (estimated GFR > 60 ml/min per 1.73 m² and urine albumin-to-creatinine ratio [uACR] < 300 mg/g).

Methods: The baseline LTL was measured by real-time polymerase chain reaction in the SMART2D cohort (n = 691) with a median follow-up of 3 years. Albuminuria progression was defined as a change in albuminuria category to a higher category and at least 30% increase in uACR from baseline in 3 years.

Results: Progressors (n = 123) had significantly shorter median LTL compared with nonprogressors (n = 568) (0.58 [0.38–0.79] vs. 0.62 [0.45–0.88], P = 0.039). Compared with subjects with longer LTL (fourth quartile), subjects with shorter LTL (first quartile) had 1.93-fold (1.04–3.60, P = 0.038) increased risk for albuminuria progression after adjustment for traditional risk factors. The association of LTL with microalbuminuria to macroalbuminuria progression was stronger than its association with normoalbuminuria (odds ratio [OR]: 1.54; 95% confidence interval [CI]: 1.02–2.32; P = 0.042 vs. OR: 1.13; 95% CI: 0.91–1.40; P = 0.263 per 1-SD decrement in natural log-transformed LTL).

Conclusion: Therefore, our results demonstrated that in patients with T2D with preserved renal filtration function, LTL predicts albuminuria progression beyond traditional risk factors, suggesting LTL may be a novel biomarker for DKD progression.

Kidney Int Rep (2018) 3, 592–601; https://doi.org/10.1016/j.ekir.2017.12.005
KEYWORDS: diabetes kidney disease; telomeres
© 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and cardiovascular mortality.¹² DKD is characterized by the presence of albuminuria and/or decline in glomerular filtration rate (GFR).³ Although microalbuminuria is clinically the first indicator of incipient DKD, DKD is a heterogeneous disease, both in terms of its clinical manifestations and rate of decline in renal function.⁴–⁸ Despite improved management of known risk factors, the residual risk for DKD still remains high, suggesting our incomplete understanding in the pathophysiology of DKD.⁹

Telomeres are tandem repeats made up of TTAGGG sequence and proteins found at the ends of chromosomes, and protects chromosomal stability.¹⁰ Telomeres naturally shorten with each cell division, as conventional DNA replicative enzymes cannot fully replicate telomere ends. Critically short telomere length, termed the HayFlick limit, triggers cell senescence and apoptosis.¹¹–¹³ Several epidemiological studies have shown that short telomeres are associated with age-related disorders, such as cardiovascular and neurodegenerative disease, cancer,¹⁴–¹⁶ and metabolic syndrome.¹⁷ Therefore, decreased telomere length is suggested to be an indicator of biological age and has been extensively studied as a potential marker for disease risk and progression.¹⁸–²¹ Accumulating evidence has begun to demonstrate the link between telomeres and pathogenesis of diabetes and renal disease. Experimental data from mouse models and humans have shown that short telomeres lead to beta cell dysfunction and defects in the insulin signaling pathway, increasing the susceptibility to and more severe diabetes than...
controls.22,23 A series of prospective studies mainly in non-Asian cohorts have confirmed a clear association between short telomere length and incident type 2 diabetes (T2D).24–26 Moreover, a recent study in Europeans found that short leukocyte telomere length (LTL) is also associated with increased risk for all-cause mortality in patients with T2D.27

Telomere shortening is also accelerated by deregulated renin-angiotensin system, inflammation, and chronic exposure to hyperglycemia,28–30 which are all risk factors associated with DKD.31 Several lines of evidence have demonstrated the association of telomere length with renal disease.32,33 Betjes et al.34 found that telomeres in T cells were shorter in patients with end-stage renal disease compared with healthy individuals in a cross-sectional study. Increased expression of cellular senescence markers was also observed in renal tissue from patients with T2D with renal disease.30 In agreement, a cross-sectional study found that telomere lengths were significantly shorter in patients with T2D with microalbuminuria as compared with patients with T2D with normal albuminuria.35 Prospective association between LTL and renal disease progression in a European population with type 1 diabetes (T1D) by Fyhrquist et al.36 demonstrated that short telomeres are associated with increased risk for albuminuria progression, whereas Raschenberger et al.37 showed that association between short LTL and chronic kidney disease progression was stronger in individuals with diabetes. However, the latter study included individuals with impaired renal function.

The natural course of DKD is less understood in patients with T2D as compared with T1D, as diagnosis is delayed by many years, and the prevalence of DKD is approximately twofold to threefold higher in Asian compared with Caucasian individuals.38 Given the roles of telomeres in aging, diabetes, and renal function, we hypothesized that LTL may be involved in deterioration of renal function in Asian patients with T2D with preserved renal function. Therefore, using a diverse sample with T2D and preserved renal filtration function, we investigated the association of LTL with DKD progression as measured by albuminuria progression in a prospective cohort in Asian patients with T2D.

**METHODS**

**Study Population**

This prospective study is nested within the Singapore Study of Macro-angiopathy and Micro-Vascular Reactivity in Type 2 Diabetes (SMART2D). Briefly, 2058 adult participants (21 years and older) with T2D were recruited from a regional hospital and a community medical center in the northern part of Singapore from August 2011 to March 2014. Three years after enrollment date, participants were recalled consecutively for the planned 3-year follow-up study. Given that this was an ongoing study, at the time the study commenced, we had 1066 patients’ follow-up (censored at July 2016 for this study) (Supplementary Figure S1). The exclusion criteria included the following: T1D, pregnant subjects, subjects with active inflammation (e.g., systemic lupus erythematosus) and cancer, subjects taking nonsteroidal anti-inflammatory drugs on the same day of clinical/vascular/biomedical assessment, or subjects on oral steroids equivalent to >5 mg/d prednisolone, as described previously.39,40 Subjects would be excluded when involvement of other causes of renal disease was suspected. The SMART2D study and the follow-up of patients complies with Helsinki Declaration, has been approved by our domain-specific ethical review board, and written informed consent was obtained from all participants.

**Clinical and Biochemical Assessments**

Detailed information on collection of baseline data and biological samples has been described previously.40 Briefly, blood pressure was measured by a sphygmomanometer and average of 3 readings was used. Blood and urine (spot urine collected in the morning void) specimens were collected after overnight fast. HbA1c was measured by point-of-care immunoassay analyzer (DCA Vantage Analyzer; Siemens AG, Erlangen, Germany). Creatinine, triglycerides, and high-density lipoprotein and low-density lipoprotein cholesterol were quantified by enzymatic methods (Roche/Hitachi Cobas C System; Roche Diagnostic GmbH, Basel, Switzerland). Urinary albumin was measured based on a solid-phase competitive chemiluminescent enzymatic immunoassay (Immulite; Diagnostic Products Corp, Gwynedd, UK). Albuminuria level was expressed as albumin-to-creatinine ratio (ACR, mg/g). The estimated GFR (eGFR) was calculated based on Chronic Kidney Disease Epidemiology Collaboration equation. Baseline and follow-up biochemical measurements were performed in the same clinical laboratory, which is accredited by the College of American Pathologists.

**Definitions of Albuminuria Progression**

Albuminuria status was categorized according to American Diabetes Association criteria as normal to mildly elevated (ACR <30 mg/g, “normoalbuminuria”), moderately elevated (ACR 30–299 mg/g, “microalbuminuria”) or severely elevated (ACR >300 mg/g, “macroalbuminuria”). Progression of albuminuria was defined as changes from normoalbuminuria to microalbuminuria or macroalbuminuria or from microalbuminuria to macroalbuminuria36 and more than 30%
increase in urine ACR (uACR) from baseline as used in the CANVAS study. Regression was defined as micro- to normoalbuminuria transition. Nonprogressors was defined as no change or regression in albuminuria levels. Only participants with eGFR level of >60 ml/min per 1.73 m² or greater and uACR <300 mg/g at baseline and followed-up for 2 years or longer were included for the current study (n = 691) (Supplementary Figure S1).

Measurement of LTL
Telomere length was measured at baseline and compared as telomere to single-copy gene ratio (T/S) using quantitative polymerase chain reaction (PCR), as described earlier. Telomeric (T) DNA and β-globin (S), used as internal control to normalize the amount of DNA loaded, was amplified from each sample. For standard, 1 reference DNA sample (commercially available human G304A DNA) was serially diluted in water by twofold dilution to produce 6 DNA concentrations from 40 to 1.25 ng in 5 µl. To reduce interassay variability, telomere and β-globin were analyzed on the same plate. Additionally, HepG2 DNA (experimental control) was run in every plate, and the average normalizing factor was used to correct the participant DNA samples to obtain the final T/S ratio (adjusted T/S ratio). All samples, standards, and controls were run in duplicate and the average values were used for the analyses. A standard curve derived from reference sample was used to transform the cycle threshold into nanograms of DNA. The amount of telomeric DNA (T) was divided by the amount of single-copy control gene DNA (S), producing a relative measurement of the telomere length (T/S ratio). The coefficients of variation within duplicates of the telomere and single-gene assay were less than 2%. The reported interassay coefficient of variation for the quantitative PCR across less than 12%. All quantitative PCR experiments were performed by the same individual and were blinded for the phenotype of the participants.

Statistical Analysis
Continuous variables with normal distribution were expressed as the mean ± SD, whereas non-normally distributed variables were presented as median and interquartile ranges (IQR). Categorical data were expressed as proportions. LTL, triglycerides, and uACR were natural logarithmically transformed due to their skewed distribution. Comparisons between groups were performed by independent-sample t-test for normally distributed variables, Mann-Whitney U test for nonparametric distributions, and χ² test for categorical variables (Table 1). Participants were also divided into quartiles based on LTL levels to visualize clinical and biochemical characteristics. One-way analysis of variance or χ² test was applied to analyze the differences in continuous or categorical variables across quartiles (Table 2). The association between LTL quartiles and the outcomes were analyzed using binary logistic regression models and adjusting for traditional risk factors, such as age, gender, ethnicity, duration of diabetes, body mass index (BMI), systolic blood pressure, HbA1c, lipid profiles, baseline eGFR and uACR, the key risk factors for DKD progression, as well as usage of insulin and renin-angiotensin system antagonists. Highest LTL quartile (longer LTL) was taken as reference category (Table 3).

Given that albuminuria progression included transition from normoalbuminuria to microalbuminuria, or from normoalbuminuria or microalbuminuria to macroalbuminuria, and macroalbuminuria is a risk factor for chronic kidney disease and end-stage renal disease, we further performed subgroup analysis to examine the association of 1-SD decrement of natural log-transformed LTL with risk for progression from normo- to microalbuminuria and from normo- or microto macroalbuminuria (Table 4). Additionally, participants with albuminuria regression (n = 57) were excluded from the control group in albuminuria progression analysis.

Next, we calculated the area under the receiver-operating characteristic curve to evaluate the predictive performance of the models after adding LTL. Given that area under the receiver-operating characteristic curve assesses risk rankings instead of clinically important relative differences in risk magnitude, we used integrated discrimination improvement to measure the separation between progressors and nonprogressors in terms of average predicted risk. As the risk category for renal progression in T2D was unknown, we used the category-free (continuous) net reclassification improvement to calculate the sum of the net percentages of the subjects with and without rapid renal progression being correctly assigned a different predicted risk.

All analyses were performed using SPSS version 22 (SPSS Inc, IBM Corporation, Chicago, IL) and R software (version 3.3.2). A 2-sided P < 0.05 was considered statistically significant.

RESULTS
Baseline Characteristic Stratified by Albuminuria Progression Status
Table 1 illustrates the baseline characteristics of the participants in this study. There were 123 progressors and 568 nonprogressors identified and their median follow-up was 3.1 (IQR 3.0–3.2) years and 3.2 (IQR 3.1–3.3) years, respectively. At baseline, progressors had higher BMI, systolic blood pressure, longer duration of...
diabetes, and were more likely to be Malay as compared with nonprogressors. No differences between progressors and nonprogressors were observed regarding age, gender, HbA1c level, lipid profiles, smoking status, and cardiovascular disease history. The eGFR levels were compatible between the groups, but uACR level was significantly higher in progressors as compared with nonprogressors (21 [IQR 10–45] and 11 [IQR 4–37] μg/mg). Notably, LTL was significantly shorter in progressors as compared with nonprogressors (0.58 [IQR 0.38–0.79] vs. 0.62 [IQR 0.49–0.88], P = 0.039) (Table 1).

**Baseline Characteristics of Participants Stratified by LTL**

We further divided participants into quartiles according to LTL to visualize the relationship between LTL and clinical characteristics at baseline (Table 2). As expected, there was a progressive decline in LTL with increasing age. Participants with shorter LTLs were older as compared with those with longer LTLs (57.8 ± 9.8 and 54.1 ± 10.1 years, P = 0.001). Compared with participants with longer LTL (highest quartile), those with shorter LTL had a lower body weight (P = 0.089), higher uACR (P = 0.014), and were more likely to be Chinese (P < 0.0001). No significant differences in HbA1c levels, diabetes duration, and lipid profiles were observed among participants across different LTL quartiles.

LTL was inversely correlated with age (rho: −0.174; P < 0.0001), diabetes duration (rho: −0.105; P = 0.006), and uACR (rho: −0.117; P = 0.002) and positively correlated with BMI (rho: 0.087; P = 0.022) and low-density lipoprotein cholesterol (rho: 0.078; P = 0.040) (Supplementary Table S1). When adjusted LTL for age, the observed correlation between LTL and clinical variables were attenuated. Multivariable linear regression analysis showed that LTL was associated with age (β: −0.011; P < 0.0001) and uACR (β: −0.045; P = 0.002) independently after adjusting for age, gender, HbA1c, diabetes duration, BMI, systolic blood pressure, lipid profiles, and eGFR (Supplementary Table S2).

**Baseline LTL Independently Predicted Albuminuria Progression**

In primary analysis, we combined participants with stable albuminuria (n = 511) and albumin regression (n = 57) as controls. Logistic regression showed that
Table 2. Baseline characteristics of patients with type 2 diabetes according to leukocyte telomere length quartile

| Variables          | Quartile 1 (n = 169) | Quartile 2 (n = 171) | Quartile 3 (n = 177) | Quartile 4 (n = 174) | P       |
|--------------------|----------------------|----------------------|----------------------|----------------------|---------|
| LTL (T/S ratio)    | 0.33 ± 0.09          | 0.52 ± 0.04          | 0.72 ± 0.08          | 1.16 ± 0.34          | <0.0001 |
| Age (yr)           | 57.8 ± 9.8           | 57.7 ± 9.7           | 55.4 ± 9.5           | 54.1 ± 10.1          | 0.001   |
| Female (%)         | 52.1                 | 47.4                 | 55.4                 | 52.9                 | 0.507   |
| Ethnicity (%)      |                      |                      |                      |                      |         |
| Chinese            | 68.0                 | 57.9                 | 49.2                 | 48.3                 |         |
| Malay              | 11.2                 | 15.8                 | 23.2                 | 28.7                 |         |
| Indian             | 20.7                 | 26.3                 | 27.7                 | 23.0                 |         |
| Body weight (kg)   | 69.5 ± 14.1          | 70.7 ± 15.2          | 71.8 ± 14.2          | 73.6 ± 16.0          | 0.089   |
| BMI (kg/m²)        | 27.0 ± 4.9           | 27.4 ± 6.1           | 27.8 ± 4.7           | 28.1 ± 5.5           | 0.218   |
| Current smokers (%)| 9.5                  | 5.8                  | 8.0                  | 8.6                  | 0.644   |
| CVD history (%)    | 8.8                  | 17.3                 | 11.4                 | 12.0                 | 0.587   |
| HbA1c (%)          | 7.69 ± 1.18          | 7.59 ± 1.24          | 7.55 ± 1.16          | 7.63 ± 1.32          | 0.740   |
| FPG (%)            | 7.99 ± 2.53          | 7.67 ± 2.51          | 7.97 ± 2.25          | 7.79 ± 2.40          | 0.557   |
| Diabetes duration (yr) | 10.7 ± 8.7         | 10.1 ± 7.8           | 9.6 ± 7.5            | 9.4 ± 8.8            | 0.437   |
| Systolic BP (mm Hg) | 137 ± 18            | 138 ± 16             | 136 ± 16             | 134 ± 14             | 0.214   |
| Diastolic BP (mm Hg) | 78.8 ± 8.6         | 78.8 ± 9.4           | 80.0 ± 9             | 78 ± 9               | 0.486   |
| Total cholesterol (mM) | 4.36 ± 0.85       | 4.29 ± 0.86          | 4.50 ± 0.98          | 4.41 ± 0.96          | 0.202   |
| HDL-C (mM)         | 1.34 ± 0.39          | 1.33 ± 0.46          | 1.26 ± 0.31          | 1.29 ± 0.30          | 0.180   |
| LDL-C (mM)         | 2.69 ± 0.72          | 2.63 ± 0.75          | 2.87 ± 0.85          | 2.79 ± 0.87          | 0.023   |
| Triglycerides (mM) | 1.57 (1.06–1.86)     | 1.28 (0.94–1.81)     | 1.45 (1.08–1.91)     | 1.23 (0.95–1.84)     | 0.104   |
| Renal function     |                      |                      |                      |                      |         |
| eGFR (ml/min per 1.73 m²) | 98.6 ± 14.9     | 95.6 ± 15.0          | 98.2 ± 16.2          | 98.6 ± 15.6          | 0.301   |
| Usage of medication (%) |                    |                      |                      |                      |         |
| Metformin          | 87.5                 | 83.5                 | 89.8                 | 80.9                 | 0.084   |
| Insulin            | 23.2                 | 17.2                 | 25.4                 | 19.1                 | 0.221   |
| Statin             | 84.5                 | 81.8                 | 82.5                 | 76.3                 | 0.244   |
| RAS antagonist     | 58.4                 | 50.6                 | 46.0                 | 55.2                 | 0.108   |

Data are described as mean ± SD or median (25th, 75th interval) for skewed variables or proportion of participants (%) where appropriate. Bold values represent statistically significant data.

BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LTL, leukocyte telomere length; RAS, renin-angiotensin system; T/S ratio, telomere to single copy gene ratio; uACR, urine albumin creatinine ratio.

individuals with LTL in the lowest quartile (shorter LTL) were associated with an increased risk for albuminuria progression (odds ratio [OR]: 2.10; 95% confidence interval [CI]: 1.15–3.83; P = 0.016; Model 1 adjusted for age, gender, ethnicity, HbA1c, and diabetes duration) compared with those with LTL in the highest quartile (longer LTL). Further adjustment for BMI, systolic blood pressure, and triglyceride level did not attenuate the association (Model 2) (Table 3). The association between LTL and risk for albuminuria progression remained significant after additional adjustment for baseline eGFR and uACR (OR: 1.93; 95% CI: 1.04–3.60; P = 0.038). Usages of medications did not materially alter the independent association of short LTL and increased risk for albuminuria progression (OR: 1.90; 95% CI: 1.02–3.54; P = 0.044; Model 4); however, individuals in second and third quartiles did not show significantly increased risk for albuminuria progression as compared with those in the fourth quartile.

Next, we assessed the improvement in risk discrimination after adding LTL into the model with traditional risk factors, such as age, gender, ethnicity, diabetes condition, blood pressure, BMI, triglycerides, baseline renal function, and medications usage (Model 4). Inclusion of LTL in the model 4 did not significantly improve area under the receiver-operating characteristic curve (from 0.675 to 0.687, P = 0.201) (Supplementary Table S3). Given that area under the receiver-operating characteristic curve is an insensitive indicator of added value of biomarker, we calculated the integrated discrimination improvement and category-free net reclassification improvement. Including LTL significantly improved the predictive performance of albuminuria as reflected by an increased category-free net reclassification improvement of 0.428 (95% CI: 0.243–0.613; P = 1e-5) and integrated discrimination improvement of 0.063 (95% CI: 0.63–0.124; P < 0.001).

Sensitivity Analysis

Exclusion of participants with albuminuria progression (n = 57) in controls did not alter the association of LTL and albuminuria progression (quartile 1 vs. quartile 4) (OR: 1.93; 95% CI: 1.02–3.68; P = 0.045 vs. OR: 1.54; 95% CI: 10.02–2.32; P = 0.042) in primary analysis. In subgroup analysis, we examined the association between LTL and transition from normoalbuminuria to...
Table 3. Logistic regression analysis for association of leukocyte telomere length with albuminuria progression

| Variables          | Model 1 OR (95%CI) | Model 2 OR (95%CI) | Model 3 OR (95%CI) | Model 4 OR (95%CI) |
|--------------------|--------------------|--------------------|--------------------|--------------------|
| LTL Quartile 1     | 2.10 (1.15−3.83)   | 2.12 (1.15−3.89)   | 1.93 (1.04−3.80)   | 1.90 (1.02−3.54)   |
| Quartile 2         | 1.64 (0.89−3.02)   | 1.62 (0.87−3.00)   | 1.52 (0.81−2.86)   | 1.50 (0.80−2.85)   |
| Quartile 3         | 1.81 (1.00−3.26)   | 1.73 (0.95−3.15)   | 1.61 (0.87−2.95)   | 1.56 (0.85−2.88)   |
| Quartile 4         | -                  | -                  | -                  | -                  |
| Age (yr)           | 1.00 (0.98−1.02)   | 1.00 (0.97−1.02)   | 0.98 (0.95−1.01)   | 0.98 (0.95−1.01)   |
| Female             | 1.13 (0.76−1.69)   | 1.03 (0.68−1.56)   | 1.25 (0.80−1.97)   | 1.26 (0.80−1.98)   |
| Male               | -                  | -                  | -                  | -                  |
| Maley             | 1.82 (1.11−2.97)   | 1.61 (0.97−2.68)   | 1.37 (0.81−2.30)   | 1.34 (0.79−2.26)   |
| Indian             | 0.79 (0.47−1.33)   | 0.77 (0.45−1.31)   | 0.76 (0.45−1.31)   | 0.75 (0.44−1.29)   |
| Chinese           | -                  | -                  | -                  | -                  |
| HBAlc (%)          | 0.98 (0.62−1.16)   | 0.95 (0.80−1.14)   | 0.94 (0.78−1.13)   | 0.94 (0.78−1.13)   |
| Diabetes duration (yr) | 1.03 (1.01−1.06) | 1.03 (1.01−1.06) | 1.03 (1.00−1.05)   | 1.02 (1.00−1.05)   |
| BMI (kg/m²)        | 1.06 (1.02−1.10)   | 1.04 (1.00−1.09)   | 1.04 (1.00−1.09)   | 1.04 (1.00−1.09)   |
| SBP (mm Hg)        | 2.68 (1.37−4.92)   | 1.97 (1.02−3.86)   | 1.97 (1.02−3.86)   | 1.97 (1.02−3.86)   |
| Triglycerides (mmol/L) | 1.06 (0.67−1.68)  | 0.93 (0.58−1.47)   | 0.93 (0.58−1.50)   |                     |
| uACR (µg/mg)       | 1.31 (1.12−1.52)   | 1.31 (1.11−1.53)   |                     |                     |
| eGFR (ml/min per 1.73 m²) | 0.99 (0.97−1.00) | 0.99 (0.97−1.00)   |                     |                     |
| RAS antagonists    | 0.97 (0.62−1.52)   |                     |                     |                     |
| Statin             | 1.29 (0.71−2.33)   |                     |                     |                     |

Data are ORs (95% CIs) estimated for continuous and categorical variables in different models. LTL was divided into quartiles and quartile 4 (longest LTL) was used as reference. Bold values represent statistically significant data (P < 0.05).

microalbuminuria and from normo- or micro- to maceralbuminuria separately (Tables S4 and S5). The association of LTL with progression from normo- or micro- to macroalbuminuria (n = 35) was stronger than normo- to microalbuminuria (n = 88) (OR: 1.54; 95% CI: 1.02−2.32; P = 0.042 vs. OR: 1.13; 95% CI: 0.91−1.40; P = 0.263) (Table 4).

DISCUSSION

In this prospective cohort of multiethnic Asian population, we found that LTL independently predicted the progression of albuminuria in T2D with preserved renal filtration function (eGFR >60 ml/min per 1.73 m² and uACR <300 µg/mg). Participants with shorter LTL (lowest quartile) were at twofold increased risk for albuminuria progression as compared with those with longer LTL (highest quartile). Furthermore, the association of LTL and albuminuria progression is independent of traditional risk factors, including hypertension, hyperglycemia, long diabetes duration, and dyslipidemia, as well as existing kidney function impairment, suggesting short LTL may be a novel biomarker for DKD progression.

Previously, in a prospective study involving patients with T1D, shorter LTL also predicted the risk for albuminuria progression. 36 Although short telomeres are also associated with decline in renal function in nondiabetic conditions, in a recent study that included patients with T1D or T2D with mild to severe chronic kidney disease, association of LTL with chronic kidney disease progression was the strongest in patients with diabetes. 37 Our study not only provided the necessary evidence of association of short LTL and albuminuria progression in Asian patients with T2D, it also demonstrated the consistency of short LTL as a potential marker for increased risk for renal disease across different ethnic groups. Furthermore, the prognostic significance of LTL in albuminuria progression was independent of known risk factors, suggesting that it may influence DKD risk through biological pathways beyond established risk factors.

In our study, compared with individuals in the fourth quartile, only individuals in the first quartile (shortest LTL) had significantly increased risk of albuminuria...
progression. In contrast, although there was a relative 50% increased risk in albuminuria progression in both second and third quartiles as compared with the fourth quartile, these differences were nonsignificant, indicating a nonlinear relation between LTL and albuminuria progression in the Asian population. This is consistent with previous observations demonstrating the nonlinear association of telomere length with incident diabetes, coronary heart disease, and cancer.\(^\text{26,43,46}\)

This is in line with the Hayflick limit hypothesis of telomeres.\(^\text{13}\) In our study, there appears to be a critical threshold value between first and second quartiles beyond which replicative senescence and consequently negative cascade of biological events may lead to propensity of DKD progression.

In the largest single telomere length assay performed in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, it was shown that LTL variation increases with age, demonstrating the influence of nongenetic factors.\(^\text{47}\) A series of studies have demonstrated that oxidative stress plays a major role in telomere attrition.\(^\text{39}\) Furthermore, telomere repeats are more sensitive to oxidative stress-induced damage as compared with nontelomeric regions.\(^\text{48}\) A recent study by Sun \textit{et al.},\(^\text{49}\) using a novel technique that measures oxidative damage at telomere real-time, showed that oxidative telomere damage leads to telomere shortening, providing another clue as to how oxidative damage may contribute significantly to telomeric erosion. Biologically, data from animal models demonstrated that telomere dysfunction represses expression of peroxisome proliferator–activated receptor gamma, coactivator 1 alpha and beta, leading to impaired mitochondria function, decreased gluconeogenesis, and increase in reactive oxygen species level.\(^\text{50}\) A recent study revealed that patients with diabetic nephropathy have reduced mitochondrial DNA content in the circulation, and reduced maximal respiration and reserve capacity compared with diabetic patients without diabetic nephropathy, suggesting that systemic mitochondrial dysfunction initiated by hyperglycemia-induced mitochondrial DNA damage may be involved in the development of diabetic nephropathy.\(^\text{51}\)

Although we do not have evidence on the oxidative stress level in our study cohort, it is known that renal cells are subjected to ongoing replicative stress, which accelerates telomere shortening and reduces proliferation capacity, resulting in less efficient regeneration and repair of tissue.\(^\text{32,52}\) Therefore, it is possible that during the early stages of DKD, short telomeres may predispose patients with T2D to be more susceptible to adverse metabolic milieu and therefore accelerated DKD progression. In a subgroup analysis, we found a significant association between shorter LTL and progression from normo- or micro- to macroalbuminuria, but not with progression from normo- to microalbuminuria, further supporting the hypothesis that LTL also represents environmental impact on renal function. However, given the small sample size in this subgroup analysis, this warrants further investigation in a larger cohort with longer follow-up.

The inverse correlation between LTL and age has been well documented in clinical studies, including this study. Besides age, other clinical variables have been shown to be associated with LTL. Albuminuria levels were independently associated with LTL at cross-sectional levels, further supporting the close relationship between early renal impairment and short telomeres. A recent clinical study in American Indian individuals showed that short LTL was associated with obesity.\(^\text{53}\) In contrast, we found a positive correlation between LTL and BMI, which was attenuated when adjusted for age. Interestingly, we found that BMI independently predicted progression from normo- to microalbuminuria beyond traditional risk factors.

The strengths of the current study include a prospective design, a relatively large sample size of multiethnic individuals in Singapore, and detailed clinical phenotyping. In our analysis, we also examined the added value of LTL beyond albuminuria and traditional clinical risk factors for DKD, including commonly prescribed medications such as renin-angiotensin system antagonists. This is also essential given that the deregulated renin-angiotensin-aldosterone system is suggested to be a contributor to telomere shortening.\(^\text{28}\) This study has limitations that should be acknowledged. First, we measured mean LTL using a PCR-based assay that does not quantify absolute telomere length as compared with Southern blotting. LTL was also measured in blood leukocytes and not the target organs, such as kidney, because widespread renal biopsies are neither practical nor ethical to carry out. However, it has been shown that telomere length measurement with quantitative PCR and Southern blotting have strong concordance,\(^\text{54}\) and telomere length in different tissues may be highly correlated.\(^\text{55}\) Second, we used a single measurement of uACR at baseline and follow-up from spot urine samples, which may raise concern with some misclassification, given that there is considerable intraindividual variation in albuminuria, which may affect classification of DKD progression.\(^\text{3}\) Moreover, a higher random ACR and eGFR measurement variation may reduce the statistical power and tend to lead the outcome to false negative. In this regard, the 1-time measurement may not be a major concern for the positive findings in our current study. Lambers Heerspink \textit{et al.}\(^\text{56}\) previously demonstrated that uACR from spot urine samples
correlates with 24-hour urine protein and is clinically relevant for predicting progression. Furthermore, in addition to increase in uACR categories, we included 30% increase in uACR from baseline to define our progressors. Last, and more importantly, because of the nature of the study design, we cannot elucidate the mechanisms underlying the linkage between shortened telomeres to the progression of renal disease. A larger cohort with longer follow-up is warranted to demonstrate the association of LTL with DKD progression, including end-stage renal disease.

In conclusion, our results indicate that LTL is independently associated with albuminuria progression in patients with T2D with early-stage DKD (eGFR > 60 ml/min per 1.73 m²) in Asian individuals. We propose that a shorter LTL may be a biomarker for propensity of renal disease progression in patients with diabetes, although the biological linkage between shorter leukocyte LTL and propensity for renal impairment in the kidney remains to be elucidated.

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENTS

This study was supported by Alexandra Health Enabling Grant (AHEG1622) and National Medical Research Council Singapore (NMRC/CIRG 1398/2014). We thank Mr. Darren Yeo, Dr. Li Na, Ms. Clara Chan, and research nurses from the Clinical Research Unit at Khoo Teck Puat Hospital, Singapore, for assistance with participant recruitment and data input for the SMART2D and follow-up study.

AUTHOR CONTRIBUTIONS

RLG designed the study, research the data, and wrote the manuscript; YM measured the LTL and researched the data. SL and J-JL reviewed the data, edited the manuscript, and contributed to the critical discussion of the work. SCL critically reviewed and edited the manuscripts, is the guarantor of this work, and takes responsibility for the integrity of the data.

SUPPLEMENTARY MATERIAL

Figure S1. Participant recruitment in this study.

Table S1. Values of Spearman correlation coefficient between leukocyte telomere length and clinical variables.

Table S2. Association of clinical variables with leukocyte telomere length in multivariable linear regression model.

Table S3. Odds ratio (OR) and area under the receiver-operating characteristic curve by logistic regression models for prediction of outcome by leukocyte telomere length (LTL) and albuminuria as categorical or continuous variable.

Table S4. Logistic regression analysis for association between per SD in leukocyte telomer length (LTL) (natural log transformed) and albuminuria progression (normo- to microalbuminuria).

Table S5. Logistic regression analysis for association between per SD in leukocyte telomer length (LTL) (natural log transformed) and albuminuria progression (normo- or micro- to macroalbuminuria).

Supplementary material is linked to the online version of the paper at http://www.kireports.org/.

REFERENCES

1. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813–1821.
2. Kong AP, Xu G, Brown N, et al. Diabetes and its comorbidities—where East meets West. Nat Rev Endocrinol. 2013;9:537–547.
3. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864–2883.
4. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37:867–875.
5. Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab. 2012;38:291–297.
6. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73–81.
7. Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment c0-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32:1497–1502.
8. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91:1300–1311.
9. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010;6:19–25.
10. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–1138.
11. Opprsko PL, Shary JW. Telomere-associated aging disorders. Ageing Res Rev. 2017;33:52–66.
12. Allsopp RC, Harley CB. Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res. 1995;219:130–136.
13. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614–636.
14. D’Mello MJ, Ross SA, Briel M, et al. Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis. Circ Cardiovasc Genet. 2015;8:82–90.
15. Haycock PC, Heydon EE, Kaptoge S, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2014;349:g4227.

16. Ma SL, Lau ES, Suen EW, et al. Telomere length and cognitive function in southern Chinese community-dwelling male elders. *Age Ageing*. 2013;42:450–455.

17. Revesz D, Milaneschi Y, Verhoeven JE, et al. Longitudinal associations between metabolic syndrome components and telomere shortening. *J Clin Endocrinol Metab*. 2015;100:3050–3059.

18. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. *Curr Mol Med*. 2005;5:197–203.

19. Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. *Science*. 2015;350:1193–1198.

20. Codd V, Nelson CP, Albrecht E, et al. Identification of seven loci affecting mean telomere length and their association with disease. *Nat Genet*. 2013;45:422–427, 427.e421–422.

21. Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? *Epidemiol Rev*. 2013;35:112–131.

22. Guo N, Parry EM, Li LS, et al. Short telomeres compromise beta-cell signaling and survival. *PLoS One*. 2011;6:e17858.

23. Kuhlow D, Florian S, von Figura G, et al. Telomerase deactivation impairs glucose metabolism and insulin secretion. *Aging (Albany NY)*. 2010;2:650–658.

24. Zhao J, Miao K, Wang H, et al. Association between telomere length and type 2 diabetes mellitus: a meta-analysis. *PLoS One*. 2013;8:e79983.

25. Testa R, Olivieri F, Sirolla C, et al. Leukocyte telomere length is associated with complications of type 2 diabetes mellitus. *Diabet Med*. 2011;28:1388–1394.

26. Zhao J, Zhu Y, Lin J, et al. Short leukocyte telomere length predicts risk of diabetes in American Indians: the strong heart family study. *Diabetes*. 2014;63:354–362.

27. Bonfigli AR, Spazzafumo L, Prattichizzo F, et al. Leukocyte telomere length and mortality risk in patients with type 2 diabetes. *Oncotarget*. 2016;7:50835–50844.

28. Vasan RS, Demissie S, Kimura M, et al. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. *Circulation*. 2008;117:1138–1144.

29. von Zglinicki T. Oxidative stress shortens telomeres. *Trends Biochem Sci*. 2002;27:339–344.

30. Verzola D, Gandolfo MT, Gaetani G, et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. *Am J Physiol Renal Physiol*. 2008;295:F1563–F1573.

31. Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. *Adv Chronic Kidney Dis*. 2014;21:260–266.

32. Wills LP, Schnellmann RG. Telomeres and telomerase in renal health. *J Am Soc Nephrol*. 2011;22:39–41.

33. Wong LS, van der Harst P, de Boer RA, et al. Renal dysfunction is associated with shorter telomere length in heart failure. *Clin Res Cardiol*. 2009;98:629–634.

34. Betjes MG, Langerak AW, van der Spek A, et al. Premature aging of circulating T cells in patients with end-stage renal disease. *Kidney Int*. 2011;80:208–217.

35. Tentolouris N, Nziethuang R, Cattan V, et al. White blood cells telomere length is shorter in males with type 2 diabetes and microalbuminuria. *Diabetes Care*. 2007;30:2909–2915.

36. Fyhrrquist F, Titu A, Sajoonnma O, et al. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. *J Intern Med*. 2010;267:278–286.

37. Raschenberger J, Kollerits B, Ritchie J, et al. Association of relative telomere length with progression of chronic kidney disease in two cohorts: effect modification by smoking and diabetes. *Sci Rep*. 2015;5:11887.

38. Kanaya AM, Adler N, Moffet HH, et al. Heterogeneity of diabetes outcomes among Asians and Pacific Islanders in the US: the diabetes study of northern California (DISTANCE). *Diabetes Care*. 2011;34:930–937.

39. Liu JJ, Yeoh LY, Sum CF, et al. Vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1, is associated with diabetic kidney disease in Asians with type 2 diabetes. *J Diabetes Complications*. 2015;29:707–712.

40. Liu JJ, Tavintharan S, Yeoh LY, et al. High normal albuminuria is independently associated with aortic stiffness in patients with Type 2 diabetes. *Diabet Med*. 2014;31:1199–1204.

41. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644–657.

42. Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic Acids Res*. 2002;30:e47.

43. McGeechan K, Macaskill P, Irwig L, et al. Assessing new biomarkers and predictive models for use in clinical practice: a clinician’s guide. *Arch Intern Med*. 2008;168:2304–2310.

44. Leening MJ, Vedder MM, Witteman JC, et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. *Ann Intern Med*. 2014;160:122–131.

45. Cui Y, Cai Q, Qu S, et al. Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women’s Health Study. *Cancer Epidemiol Biomarkers Prev*. 2012;21:1807–1813.

46. Ye S, Shaffer JA, Kang MS, et al. Relation between leukocyte telomere length and incident coronary heart disease events (from the 1995 Canadian Nova Scotia Health Survey). *Am J Cardiol*. 2013;111:962–967.

47. Lapham K, Kvale MN, Lin J, et al. Automated assay of telomere length and microalbuminuria progression of diabetic nephropathy in patients with type 1 diabetes. *J Alzheimers Dis*. 2014;40:1569–1575.

48. Rossiello F, Herbig U, Longhese MP, et al. Irreparable telomeres disrupt their integrity and triggers cell death. *Science*. 2013;341:1198–1199.

49. Sun L, Tan R, Xu J, et al. Targeted DNA damage at individual loci affects mean telomere length and their association with disease. *J Clin Endocrinol Metab*. 2013;100:3050–3059.

50. Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. *Nature*. 2011;470:359–365.
51. Czajka A, Ajaz S, Gnudi L, et al. Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy. *EBioMedicine*. 2015;2:499–512.

52. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. *Proc Natl Acad Sci U S A*. 1995;92:11190–11194.

53. Chen S, Yeh F, Lin J, et al. Short leukocyte telomere length is associated with obesity in American Indians: the Strong Heart Family study. *Aging (Albany NY)*. 2014;6:380–389.

54. Aviv A, Hunt SC, Lin J, et al. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. *Nucleic Acids Res*. 2011;39:e134.

55. Gadalla SM, Cawthon R, Giri N, et al. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. *Aging (Albany NY)*. 2010;2:867–874.

56. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. *J Am Soc Nephrol*. 2010;21:1355–1360.